- cafead   Mar 30, 2021 at 10:32: PM
via Regulatory approvals are big wins for biotech companies. It is no different for cancer drug specialist Surface Oncology (NASDAQ:SURF), the shares of which were up nearly 13% in early after-hours trading Tuesday following an important nod from the U.S. Food and Drug Administration (FDA).
article source
article source